Dosimetric comparison of SBRT and HDR brachytherapy in patients from randomized study.
OC-0041
Abstract
Dosimetric comparison of SBRT and HDR brachytherapy in patients from randomized study.
Authors: S. Nonikov1, N. Ilin1, Y. Melnik1, R. Novikov1, Y. Merezhko1, S. Kanaev1
1N.N. Petrov National Research Cancer Center, Department of radiotehrapy, Saint Petersburg, Russian Federation
Show Affiliations
Hide Affiliations
Purpose or Objective
Background: There has been an increasing interest in stereotactic body therapy (SBRT) and
high dose rate brachytherapy (HDRB) in treatment of low-intermediate risk
prostate cancer. In order to compare efficacy and safety of both methods in
2018 we initiated single center prospective randomized trial.
The aim of this study was to compare dosimetric plans of patients that received
HDRB with those that were randomized to SBRT.
Material and Methods
Between
01.06.2018 and 01.07.2019, 139 men with low-intermediate risk prostate cancer were
randomized between HDRB or SBRT. Sixty-nine patients received TRUS guided HDRB in
2 fractions of 13 Gy (BED-251.3; α/β-1.5), among them 10 men received HDRB with
the low dose tunnel for urethra (D10 ur<90%). Another 70 men were treated by
SBRT in 5 fractions of 7.25Gy (BED-211.5; α/β-1.5). For comparison of dosimetric
plans we used the following parameters: V100 pr – the percentage of prostate
that received 100% of prescription does and D90 pr – minimum dose that covers
90% of prostate; D2cc rec - the maximum dose for 2cc of the rectal wall; D10 ur
– the dose that covered 10% of the urethra volume.
Results
All plans were characterized by excellent coverage of the
target (prostate). V100 and D90 for prostate were as follows: for SBRT - 91% (87.3-94.7%)
and 100.1% (99.9-100.3%); for HDRB – 94.3% (92.1-96.5%) and 104.7%
(102.3-107.1%). SBRT demonstrated uniform dose distribution with nearly
equivalent dose to the prostate and urethra (D10ur- 101%; 100.3-101.7%) and
high dose to the rectum (D2cc – 91%; 86.7-95.3%) and bladder (D2cc 100.9%;
99.6-102.2%). HDRB give the opportunity for significant reduction of the dose
to the anterior rectal wall (D2cc - 55.3%; 48.4-62.2%) with moderate dose to
the bladder (D2cc – 69%; 61.6-76.4%) and urethra (D10 – 108.3%; 105.5-111.1%).
HDRB with “tunnel for urethra” was performed only in low risk patients with
negative periurethral biopsy cores. This technique gives the opportunity to
reduce dose to the urethra (D10 – 89.4%; 86.5-92.3%) and to the bladder (D2cc -
56%; 49.1-62.94%) with moderate underdose of the prostate (central and
transitional zones).
Conclusion
Our data indicate that both HDRB and SBRT
characterized by excellent target (prostate) coverage. Important advantage of
HDRB against SBRT is significant (from 91% to 55.3%) reduction of the dose to
the rectum. HDRBT with “tunnel to urethra” reduce the dose to the urethra and
bladder neck with underdose of the central and transitional zones of prostate.